Fig. 10: CD8+ T cell responses against human tumor antigens in ABab-I mice.
From: Mice with a diverse human T cell receptor repertoire selected on multiple HLA class I molecules
Specific CD8+ T cell responses in ABab-I mice were observed after immunization with a panel of antigens. ABab-I mice were immunized (minimum twice) with an interval of at least 4 weeks between peptide injections. Seven days post-injection, peripheral blood cells were stimulated in vitro with the same specific peptides used for immunization (right), or unspecific NY-ESO peptide, APRGPHGGAASGL (left), or CD3/CD28 beads (middle, pos. control). Cells were analyzed for CD3, CD8, and intracellular IFN-γ expression by flow cytometry. Dot plots depict CD8+ IFN-γ+ T cells (gated on CD3+ lymphocytes). One representative plot out of multiple responders is given (out of 6–7 mice/antigen, 6 mice responded against KRAS, 3 mice against HPV and MAGE-A1, 2 mice responded against CMV (1 each to TPRVTGGGAM and QYDPVAALF peptides), 1 mouse responded against mCALR and MAGE-A12 peptides).
